[go: up one dir, main page]

AR017747A1 - Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico - Google Patents

Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico

Info

Publication number
AR017747A1
AR017747A1 ARP990102435A ARP990102435A AR017747A1 AR 017747 A1 AR017747 A1 AR 017747A1 AR P990102435 A ARP990102435 A AR P990102435A AR P990102435 A ARP990102435 A AR P990102435A AR 017747 A1 AR017747 A1 AR 017747A1
Authority
AR
Argentina
Prior art keywords
coating
entcric
pearls
nucleus
composition
Prior art date
Application number
ARP990102435A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22179393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR017747(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR017747A1 publication Critical patent/AR017747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composicion farmacéutica con recubrimiento entérico de alta carga de fármaco que contiene un nucleo en la forma de perla, pastilla,gránulo o partícula y un recubrimiento entérico para el nucleo, el nucleo comprende un medicamentolábi l al ácido en una cantidad dentro del rango deaproximadamente 50 a aproximadamente 100% en peso de la composicion, un aglutinante en una cantidad dentro del rango de aproximadamente 0 a aproximadamente10% en peso de la composicion, undesintegrante e n una cantidad dentro del rango de aproximadamente 0 a aproximadamente 10% en peso de la composicion, yel recubrimiento entérico que comprende un copolímero de ácido metacrílico, y un plastificante, el recubrimiento entérico queimparte proteccion al nucleopara que el nucleo se proporcione proteccion en un ambiente de pH bajo de 3 o menos, mientras que es capaz de liberar el medicamento a un pH de 4,5 osuperior, la composicion farmacéutica también comprende un anti-adherente en una cantidad dent ro del rango de aproximadamente 0,1 a aproximadamente 4,0%en peso. Las perlas así llamadas tienen excelente resistencia a la desintegracion a pH menor de 3 pero tienen excelentes propiedades de liberacion de fármacoapH mayor de 4,5. También se propo ne una nuevo método para hacer la composicion farmacéutica. Dichas composiciones son particularmente utiles para laproteccion de fármacos sensibles a un pH de 3 o menor de 3, tal como la 2,3-didesoxinosine (ddI):
ARP990102435A 1998-05-22 1999-05-21 Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico AR017747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8359798A 1998-05-22 1998-05-22

Publications (1)

Publication Number Publication Date
AR017747A1 true AR017747A1 (es) 2001-10-24

Family

ID=22179393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102435A AR017747A1 (es) 1998-05-22 1999-05-21 Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico

Country Status (39)

Country Link
US (2) US6224910B1 (es)
EP (1) EP1079809B1 (es)
JP (2) JP3798625B2 (es)
KR (1) KR100484299B1 (es)
CN (1) CN1149075C (es)
AP (1) AP1206A (es)
AR (1) AR017747A1 (es)
AT (2) ATE311859T1 (es)
AU (1) AU750911B2 (es)
BG (1) BG65398B1 (es)
BR (1) BR9815861A (es)
CA (1) CA2332922C (es)
CO (1) CO5070679A1 (es)
CY (1) CY1119543T1 (es)
CZ (1) CZ300497B6 (es)
DE (2) DE1079809T1 (es)
DK (2) DK1079809T3 (es)
DZ (1) DZ2797A1 (es)
EE (1) EE04926B1 (es)
ES (1) ES2165833T3 (es)
GE (1) GEP20033014B (es)
HU (1) HU226491B1 (es)
ID (1) ID27031A (es)
IL (1) IL139274A (es)
LT (1) LT4843B (es)
LV (1) LV12602B (es)
MA (1) MA26636A1 (es)
NO (2) NO322903B1 (es)
NZ (1) NZ508194A (es)
OA (1) OA11512A (es)
PL (1) PL193294B1 (es)
RO (1) RO121674B1 (es)
RU (1) RU2197227C2 (es)
SK (1) SK284890B6 (es)
TN (1) TNSN99097A1 (es)
TR (1) TR200003373T2 (es)
UA (1) UA69413C2 (es)
WO (1) WO1999061002A1 (es)
ZA (1) ZA993090B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
PT1065936E (pt) 1998-03-23 2009-09-24 Gen Mills Inc Encapsulação de componentes em produtos comestíveis
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
EP1341529A2 (en) * 2000-11-10 2003-09-10 F. Hoffman-la Roche AG Hydrolytically unstable compositions
WO2002081050A1 (en) * 2001-04-04 2002-10-17 Ngk Insulators, Ltd. Rain water treating device in combined sewage, and backwashing method therefor
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
CA2461653A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Edible composition and dosage form comprising an edible shell
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
US6967218B2 (en) 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
WO2003061688A1 (en) * 2002-01-21 2003-07-31 Nrl Pharma, Inc. Novel analgesics
EP1490029A4 (en) * 2002-03-22 2006-02-22 Ranbaxy Lab Ltd DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
ZA200501508B (en) * 2002-09-03 2006-10-25 Biovail Lab Inc Pharmaceuticals formulations and methods for modified release of statin drugs
CA2497896A1 (en) * 2002-09-03 2004-03-18 Biovail Laboratories Inc. Pravastatin pharmaceutical formulations and methods of their use
CA2520321A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
MXPA06006586A (es) * 2003-12-09 2007-02-21 Pharmasset Inc Metodos de dosificacion para la terapia antiviral con beta-d-2',3'-didesoxi-2',3'-dideshidro-5-fluorocitidina.
JP5032300B2 (ja) * 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
MX2007005763A (es) * 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US11744803B2 (en) 2005-07-29 2023-09-05 Stichting Groningen Centre for Drug Rese PH-controlled pulsatile delivery system, methods for preparation and use thereof
AU2006274835B2 (en) * 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
JP5284092B2 (ja) * 2005-08-15 2013-09-11 アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腸溶コーティングに適したパンクレアチンマイクロペレットコア
DK1931316T4 (en) 2005-08-15 2017-05-15 Abbott Laboratories Gmbh Controlled-release pharmaceutical compositions for use in acid-labile drugs
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
EP3659588A1 (en) 2006-01-27 2020-06-03 The Regents of The University of California Enterically coated cysteamine and salts thereof
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
AR071598A1 (es) 2008-04-24 2010-06-30 Bristol Myers Squibb Co Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer
JP5964589B2 (ja) * 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
AU2011302006A1 (en) 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
GB2484929A (en) 2010-10-25 2012-05-02 Maria Christiana Peter Geraedts An edible product including plant protein
RU2442572C1 (ru) * 2010-12-23 2012-02-20 Ольга Львовна Титова Энтеросолюбильная оболочка и композиция для ее получения
KR20120135063A (ko) * 2011-06-01 2012-12-12 닛토덴코 가부시키가이샤 입자 제제 및 그 제조 방법
US10117447B1 (en) * 2013-03-15 2018-11-06 The United States Of America, As Represented By The Secretary Of Agriculture Extrusion of high density hydroxypropylmethylcellulose edible flexible gels
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
CN104758180A (zh) * 2014-01-06 2015-07-08 山东诚创医药技术开发有限公司 一种复方制剂胶囊的二次填充方法
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3344274A4 (en) 2015-09-01 2019-05-22 First Wave Bio, Inc. METHOD AND COMPOSITIONS FOR TREATING DISEASES RELATED TO ABNORMAL INFLAMMATORY REACTIONS
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
RU2670447C2 (ru) * 2016-11-17 2018-10-23 Общество с ограниченной ответственностью "Изварино Фарма" Пероральная твердая лекарственная форма с микофенольной кислотой или ее солью для использования в качестве иммунодепрессанта для лечения или предупреждения отторжения трансплантата органа или ткани и способ ее получения
EP3630171A1 (en) 2017-05-26 2020-04-08 Animal Microbiome Analytics, Inc. Products and methods for therapeutic administration of microorganisms to non-human animals
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
CN111280449B (zh) * 2020-02-11 2022-11-11 浙江华康药业股份有限公司 一种肠内缓释糖醇添加剂及其制备方法和应用
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
WO1987001284A1 (en) 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
WO1988002629A1 (en) * 1986-10-16 1988-04-21 American Health Products Corporation 2',3'-didesoxyadenosine composition
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
SE460946B (sv) * 1987-03-16 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av kinidinglukonat
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
CA2030581C (en) * 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
JPH07509702A (ja) 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
EP0689840A1 (de) * 1994-06-28 1996-01-03 Spirig Ag Pharmazeutische Präparate Neues orales Erythromycinbase enthaltendes Arzneimittel
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I

Also Published As

Publication number Publication date
NZ508194A (en) 2003-07-25
HK1034461A1 (en) 2001-10-26
RO121674B1 (ro) 2008-02-28
HUP0101714A3 (en) 2002-10-28
ES2165833T3 (es) 2006-05-16
AT6311U1 (de) 2003-08-25
LV12602B (en) 2001-07-20
KR20010043736A (ko) 2001-05-25
JP3798625B2 (ja) 2006-07-19
JP2002516268A (ja) 2002-06-04
CZ20004362A3 (en) 2001-05-16
KR100484299B1 (ko) 2005-04-20
CY1119543T1 (el) 2018-04-04
IL139274A0 (en) 2001-11-25
ID27031A (id) 2001-02-22
AU750911B2 (en) 2002-08-01
BG105061A (bg) 2001-07-31
DK1079809T3 (da) 2006-02-20
LT4843B (lt) 2001-09-25
BG65398B1 (bg) 2008-06-30
UA69413C2 (uk) 2004-09-15
EE200000680A (et) 2002-10-15
RU2197227C2 (ru) 2003-01-27
DE1079809T1 (de) 2002-08-22
EP1079809A1 (en) 2001-03-07
DZ2797A1 (fr) 2003-12-01
ZA993090B (en) 2000-11-06
CO5070679A1 (es) 2001-08-28
CA2332922C (en) 2008-02-12
PL344259A1 (en) 2001-10-22
EP1079809B1 (en) 2005-12-07
LV12602A (en) 2001-01-20
LT2000105A (lt) 2001-04-25
NO20005879D0 (no) 2000-11-21
HUP0101714A2 (hu) 2002-01-28
OA11512A (en) 2004-02-03
BR9815861A (pt) 2001-01-16
DE69832731T2 (de) 2006-09-14
ATE311859T1 (de) 2005-12-15
IL139274A (en) 2004-12-15
AU8685498A (en) 1999-12-13
DE69832731D1 (de) 2006-01-12
MA26636A1 (fr) 2004-12-20
ES2165833T1 (es) 2002-04-01
NO20062106L (no) 1999-11-23
EP1079809A4 (en) 2001-11-07
AP2000001988A0 (en) 2000-12-31
US20010005716A1 (en) 2001-06-28
SK284890B6 (sk) 2006-02-02
GEP20033014B (en) 2003-07-25
JP2006022115A (ja) 2006-01-26
NO322903B1 (no) 2006-12-18
NO20005879L (no) 2001-01-18
WO1999061002A1 (en) 1999-12-02
TNSN99097A1 (fr) 2005-11-10
DK200200229U3 (da) 2003-01-24
CN1149075C (zh) 2004-05-12
AP1206A (en) 2003-09-18
CZ300497B6 (cs) 2009-06-03
TR200003373T2 (tr) 2001-03-21
US6224910B1 (en) 2001-05-01
CA2332922A1 (en) 1999-12-02
EE04926B1 (et) 2007-12-17
CN1294509A (zh) 2001-05-09
HU226491B1 (en) 2009-03-02
PL193294B1 (pl) 2007-01-31
SK16302000A3 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
AR017747A1 (es) Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico
ES2582646T3 (es) Formulación de comprimido recubierto y método
ES2295256T3 (es) Comprimido de liberacion controlada de clorhidrato de bupropion.
CN100490790C (zh) 一种奥美拉唑肠溶微丸胶囊及其制备方法
ES2582453T3 (es) Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada
TWI314868B (en) Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient
NZ588499A (en) Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating
BRPI0714915A2 (pt) composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
HUE032869T2 (en) The use of polymer blends for the production of coated pharmaceutical forms, as well as pharmaceutical forms containing a mixed polymer coating
JP2012153724A5 (es)
JP2016516698A5 (es)
FI4159204T3 (fi) Uudenlainen farmaseuttinen koostumus
CN102015747A (zh) 稳定的台勾霉素的组合物
SA515360408B1 (ar) تركيبات صيدلانية تشتمل على هيدرومورفون ونالوكسون
US20090060996A1 (en) Formulations of Clopidogrel Bisulphate
JP2019513800A5 (es)
ES2388880T3 (es) Composición farmacéutica que comprende olmesartán medoxomilo
JP2015120756A5 (es)
CN110876732A (zh) 一种替格瑞洛或其可药用盐的缓释组合物
JP5822758B2 (ja) 速溶性防湿フィルムコーティング製剤及びその製造方法
Radhika et al. Formulation and Evaluation of Sustained Release Matrix Tablets of Glipizide: Sustained release matrix tablets of glipizide
KR20160005022A (ko) 소바프레비르 타블렛
KR20130060220A (ko) 장용성 정제
CN104800183A (zh) 一种阿司匹林肠溶片及其制备方法和应用
JP2004522780A5 (es)

Legal Events

Date Code Title Description
FG Grant, registration